In general, the more bioavailable a substance is, the faster it is absorbed into the bloodstream. But the exact ratio varies between products. For instance, some studies indicate that CBD vaporized consumption has higher bioavailability than smoking. The same can be said for CBD oil. Bioavailability is a key factor in determining the effectiveness of a Balance Bloom CBD Gummies product. This is because it determines how long the product stays in the body. You can increase the bioavailability of a CBD product by using an absorption method that allows the compound to stay in the body for longer periods of time. The endocannabinoid system is a network of receptors that is found throughout the nervous system. The compound CBD must bind with these receptors before it is absorbed. Bioavailability is affected by several factors. Some are related to the metabolic and digestive systems. Others are based on the person's health and age. The digestive system will filter out a large portion of a compound before it can be absorbed into the body. Because of this, Balance Bloom CBD Gummies edibles will only partially absorb into the bloodstream. However, they are still a popular way to consume the substance.

After clearing its way through EU-GMP certification, a North Macedonian company is now able to export medical cannabis products to the EU. How will this affect the landscape of medical cannabis in Europe? In Macedonia, cannabis is not legal for recreational use at all, and there are no decriminalization or personal use laws to boot. However, in 2016, Macedonia did approve a bill for medical cannabis within the country. As per Macedonian laws, BalanceBloom which sync with EU laws here, oils and extracts can have up to .2% THC and still be sold without a prescription. Cannabis with any higher THC amount can be obtained through prescription. The laws allow for private citizens to make use of medical cannabis, as well as for Macedonia to enter into the legal medical cannabis market with laws to cover cultivation, production, and exportation for medicinal use. Since that time, and according to internal legislation, Macedonia has been exporting extracts, oils, and tinctures, but that’s it.

And while that does account for about 30% of the market, the great majority - 70% - relies on smokable hemp flowers, which Macedonia had not been cleared to export at all. Until now though, the EU was not included in exportable locations for any goods as no companies had EU-GMP authorization. What’s the biggest problem? One of the biggest issues for Macedonia is that cannabis flowers have not been legalized for exportation. A big factor in this inability comes from internal licensing issues that stem from allegations of corruption. The allegations centered around former Prime Minister Zoran Zaev showing preferential treatment when giving out licenses, opting to give them to friends and family members which would, in turn, benefit him personally. There were also a lot of questions and calls for specifications relating to how licensing would generally work, issues related to the program being government run, [Redirect-303] and opposition to the €500 bank guarantee that many thought would make it harder for smaller enterprises to gain ground.

With Zaev no longer in office, and with Corona issues subsiding enough to get back to regular business, the issue of Macedonia selling flowers can once again be broached. But in the meantime, while flowers might still be illegal for export, and while several companies have been awarded licensing for cultivation, only one company thus far has received EU GMP clearance to export its products (by Macedonian law) into the EU, making Macedonia a new competitor in the medicinal marijuana game there. So, who is it? The company PharmaCann Polska received the EU-GMP certification to produce cannabis extracts (still not flowers) in its North Macedonia production facility. PharmaCann is actually based out of Warsaw, Poland, and received its EU-GMP certifications in March (amid Corona), by the Chief Pharmaceutical Inspectorate of Poland, after full inspections of the facility were made. The facility is reportedly an indoor growing operation that can both cultivate and manufacture products. Zlatko Keskovski, PharmaCann’s CEO stated: "When I hear about the prices of medical cannabis extracts in Germany and other European countries, I can’t believe how expensive they are.